Global BulletinAll NewsFDA Approval AlertWomen in Oncology
Expert InterviewsAround the PracticeBetween the LinesFace OffFrom All AnglesMeeting of the MindsOncViewPodcastsTraining AcademyTreatment Algorithms with the Oncology BrothersVideos
Conferences
All JournalsEditorial BoardFor AuthorsYear in Review
Frontline ForumSatellite Sessions
CME/CE
Awareness MonthNurse Practitioners/Physician's AssistantsPartnersSponsoredSponsored Media
Career CenterSubscribe
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
Spotlight -
  • Radiation Oncology
  • Surgery
Adverse Effects
Brain Cancer
Breast CancerBreast CancerBreast Cancer
Gastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal CancerGastrointestinal Cancer
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancersGynecologic CancersGynecologic CancersGynecologic Cancers
Head & Neck Cancer
Hematologic OncologyHematologic OncologyHematologic OncologyHematologic Oncology
InfectionInfection
Leukemia
Lung CancerLung CancerLung Cancer
Lymphoma
Neuroendocrine Tumors
Oncology
Pediatric Cancers
Radiation Oncology
Sarcoma
Screening
Skin Cancer & Melanoma
Surgery
Thyroid Cancer
    • Conferences
    • CME/CE
    • Career Center
    • Subscribe

Your AI-Trained Oncology Knowledge Connection!

scout
Advertisement

NCI Addresses Tobacco- Related Cancers in Women

March 1, 2005
By Roy S. Herbst, MD, PhD
Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 14 No 3
Volume 14
Issue 3

This special “annual highlights” supplement to Oncology News International is acompilation of major advances in the management of lung cancer during 2004, asreported in ONI. Guest editor Dr. Roy Herbst discusses these advances in clinicalmanagement, with a focus on developments in adjuvant therapy for early disease,targeted therapy, and new chemotherapy findings.

BETHESDA, Maryland-Aworking group of the National CancerInstitute (NCI) has released a seriesof recommendations aimed atstimulating scientific research intotobacco-related cancers in women andtranslating discoveries into evidencebasedinterventions to prevent thecancers worldwide.The report, "Women, Tobacco,and Cancer: An Agenda for the 21stCentury," noted that the incidenceand mortality rates of smoking-relatedcancers in US women soared duringthe second half of the 20th century.Lung cancer mortality in womenincreased 600% between 1950 and1997, making it the leading cause ofcancer death in females.The NCI working group comprisedexperts from the institute, other federalagencies, nongovernment researchinstitutions, and advocacygroups. Members drew in part on informationcontained in several recentreports, including the 2001 SurgeonGeneral's report, "Women and Smoking,"which highlighted the importanceof gender-specific research intotobacco use and effects.The panel set several key goals forfuture research into tobacco-relatedcancers in women:

  • Increase our understanding ofsex differences across the broad rangeof research on women, tobacco, andcancer.
  • Develop new and more effectiveinterventions to prevent and treat tobaccouse and environmental tobaccosmoke exposure among womenand girls, especially in populations atgreatest risk; expand partnerships,networks, and innovative researchplatforms to ensure the widespreaddelivery of these interventions.
  • Improve national and globalevaluation and surveillance of thehealth hazards related to tobacco useand ETS exposure, specifically, ofwomen's and girls' knowledge, attitudes,and behaviors related to tobaccouse and associated risks.The working group emphasizedthat there is a critical need to betterunderstand sex differences as they relateto all phases of tobacco addictionand tobacco-related diseases."This includes genetic, molecular,cellular, neurobiological, biobehavioral,and hormonal factors thatplay a critical role in tobacco addictionand in the etiology of cancersand other diseases caused by tobacco,"the working group stated.Researchers also need to decipherthe etiologic role of gene-hormoneenvironmentinteractions in the cancers,and discover new methods forprevention and treatment of tobaccoaddiction. In addition, the NCI panelsaid that development of better treatmentand prevention techniques requiresidentifying the behavioral,psychosocial, sociocultural, and environmentalfactors that influence tobaccouse, exposure to second-handsmoke, and disease risk.

Translating basic and applied researchinto effective interventions willdepend on advances in four areas:

  • Using evidence from animalstudies, pilot projects, and small clinicaland community studies to developnew interventions for prevention,cessation, and treatment.
  • Finding ways to use or modifyexisting infrastructures to rapidly evaluatethe efficacy of promising treatmentsand the effectiveness and costefficiencyof proven small-scaleprograms and policies.
  • Exploring and strengthening thepositive health effects of tobacco-control policies on women and girls.
  • Monitoring the harmful effectsof tobacco marketing on females.

Delivering the proven results of researchand development efforts willdepend on finding ways to increasethe appeal, access, affordability, anduse of effective interventions, theworking group said. This, in turn, willrequire identifying and targeting messagesand strategies that successfullyinvolve individuals and organizationsin evidence-based tobacco-controlpolicies. Data from research-includingsurveillance, policy, economic,and cultural studies-need to be moreavailable to health care workers, policymakers, and the public, the paneladded.The NCI report also stressed theimportance of partnerships betweengovernment agencies, nongovernmentorganizations, private foundations,corporations, academic institutions,and community groups in acceleratingprogress in tobacco-related interventionsaimed at women and girls.Finally, the panel cited the importanceof local, national, and worldwideevaluation and surveillance indetermining the progress of efforts toreduce tobacco use, ETS exposure,and tobacco-related cancers amongwomen and girls, and to make changesin programs when needed.

Articles in this issue

Smoking Speeds Progression of Pancreas Ca
Alcohol, Obesity, and Smoking Risk Factors for HCC
Eloxatin Receives FDA Indication for Use in Adjuvant Treatment of Stage III Colon Cancer
Adding Bevacizumab Improves Response to Oxaliplatin Regimens
Capecitabine Promises Convenience, Efficacy in LARC, Five Studies Show
Avastin Enhances FOLFOX Efficacy

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!
Recent Videos
According to Jorge Nieva, MD, there are a multitude of things that can be explored to enhance the treatment landscape for lung cancer.
In a CancerNetwork® YouTube video, Cornelia Tischmacher, a mother of twins from Germany, outlined her receipt of double lung transplantation.
Ongoing ctDNA analysis may elucidate outcomes associated with divarasib plus migoprotafib for those with KRAS G12C–positive NSCLC.
Related Content

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care

Russ Conroy
September 17th 2025
Article

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 17th 2025
Podcast

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

VT3989 Receives Orphan Drug Designation for the Treatment of Mesothelioma

Roman Fabbricatore
September 17th 2025
Article

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
September 17th 2025
Podcast

A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.

COCOON Regimen Shows Promise in Mitigating Dermatologic AEs During NSCLC Treatment

ONCOLOGY Staff
September 17th 2025
Article

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

ONCOLOGY Staff
September 17th 2025
Article
Related Content

Findings from the 2025 World Conference on Lung Cancer reflected key updates in the management of NSCLC, SCLC, and other lung cancer types.

WCLC 2025: The Top 5 Takeaways Across Lung Cancer Care

Russ Conroy
September 17th 2025
Article

Georgios Evangelou, MD, MSc, speaks to the potential utility of neoadjuvant capecitabine/temozolomide in well-differentiated atypical carcinoids.

Exploring the Value of Preoperative CAPTEM in Atypical Lung NETs

Georgios Evangelou, MD, MSc
September 17th 2025
Podcast

An ongoing, open-label phase 1 study evaluating VT3989 in mesothelioma revealed positive early efficacy and encouraging safety with the agent.

VT3989 Receives Orphan Drug Designation for the Treatment of Mesothelioma

Roman Fabbricatore
September 17th 2025
Article

Rian M. Hasson Charles, MD, MPH, FACS, discusses advances in equitable lung cancer screening and her experiences as a woman in thoracic oncology.

Achieving Health Equity in Lung Cancer Surgery

Rian M. Hasson Charles, MD, MPH, FACS
September 17th 2025
Podcast

A proactive regimen reduces dermatologic AEs in patients with NSCLC who were treated with amivantamab and lazertinib, enhancing treatment adherence.

COCOON Regimen Shows Promise in Mitigating Dermatologic AEs During NSCLC Treatment

ONCOLOGY Staff
September 17th 2025
Article

The MARIPOSA trial revealed promising survival benefits with amivantamab plus lazertinib vs osimertinib for patients with EGFR-mutant lung cancer.

MARIPOSA OS Results Are Significant for EGFR+ NSCLC

ONCOLOGY Staff
September 17th 2025
Article
Advertisement
About
Advertise
CureToday.com
OncLive.com
OncNursingNews.com
TargetedOnc.com
Editorial
Contact
Terms and Conditions
Privacy
Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H,
Monroe, NJ 08831

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.